6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors
Key Takeaways
- EGFR TKIs in NSCLC span 1st-generation reversible (erlotinib, gefitinib), 2nd-generation irreversible pan-HER (afatinib, dacomitinib), and 3rd-generation mutant-selective, CNS-penetrant osimertinib, which targets sensitizing Ex19del/L858R and T790M resistance mutations while sparing wild-type EGFR.
- Next-generation ALK inhibitors (alectinib, brigatinib, lorlatinib) demonstrate superior systemic and CNS progression-free survival over crizotinib; lorlatinib uniquely overcomes the G1202R solvent-front resistance mutation but requires proactive surveillance for severe hyperlipidemia and central neuropsychiatric toxicities.
- Dual BRAF + MEK inhibition (dabrafenib + trametinib, encorafenib + binimetinib) suppresses paradoxical MAPK hyperactivation seen with single-agent BRAF inhibitors, virtually eliminating secondary cutaneous squamous cell carcinomas while necessitating protocolized management of pyrexia syndromes, serous retinopathy, and cardiomyopathy.
- Multi-targeted VEGFR TKIs (sunitinib, cabozantinib, lenvatinib, axitinib) exhibit class-effect toxicities including secondary hypertension, hand-foot skin reaction (HFSR), proteinuria, arterial thromboembolism, and subclinical hypothyroidism mediated by endothelial nitric oxide suppression and capillary rarefaction.
- Clinical oncology pharmacists optimize oral TKI efficacy and safety by managing pH-dependent bioavailability interactions (e.g., avoiding PPIs with erlotinib, gefitinib, and dasatinib) and implementing evidence-based toxicity protocols such as the STEPP minocycline and topical corticosteroid regimen for EGFR-induced acneiform rash.
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors
The development of oral small-molecule Tyrosine Kinase Inhibitors (TKIs) has revolutionized medical oncology, shifting solid tumor management from non-specific cytotoxic doublets to biomarker-directed precision therapy. Tyrosine kinases catalyze the transfer of the gamma-phosphate from adenosine triphosphate (ATP) to specific tyrosine residues on target substrate proteins, initiating downstream intracellular signaling cascades (e.g., RAS-RAF-MEK-ERK and PI3K-AKT-mTOR) that govern cellular proliferation, survival, angiogenesis, and metastatic dissemination.
Oncology clinical pharmacists must master the structural classifications, pharmacokinetics, resistance mechanisms, landmark clinical trial data, and drug-interaction profiles of solid tumor TKIs to guide evidence-based regimen selection, optimize oral bioavailability, and manage complex drug toxicities.
1. Kinase Structural Biology & Inhibitor Binding Modes
Protein kinases share a conserved catalytic domain comprising an N-terminal lobe (predominantly beta-sheets), a C-terminal lobe (alpha-helical), and a flexible hinge region that forms the deep ATP-binding cleft. Kinase inhibitors are categorized into distinct classes based on their binding conformation and catalytic interaction:
+-----------------------------------------------------------------------------+
| TYROSINE KINASE INHIBITOR BINDING MODES |
| |
| [TYPE I INHIBITORS] |
| - Bind the active ("DFG-in") kinase conformation |
| - Competitively occupy the ATP adenine-binding pocket |
| - Examples: Erlotinib, Gefitinib, Crizotinib, Alectinib |
| |
| [TYPE II INHIBITORS] |
| - Bind the inactive ("DFG-out") kinase conformation |
| - Extend into an adjacent allosteric hydrophobic back pocket |
| - Examples: Sorafenib, Sunitinib, Cabozantinib, Imatinib |
| |
| [TYPE III / IV (ALLOSTERIC) INHIBITORS] |
| - Bind allosteric pockets outside the ATP catalytic cleft |
| - Induce conformational shifts preventing kinase activation |
| - Examples: Trametinib (MEK1/2), Asciminib (BCR-ABL1 STAMP) |
| |
| [TYPE VI (COVALENT / IRREVERSIBLE) INHIBITORS] |
| - Form an irreversible Michael-addition covalent bond with a specific |
| cysteine residue near the ATP pocket (e.g., Cys797 in EGFR, Cys481 in BTK)|
| - Overcome high ATP competition; prolonged pharmacodynamic target shutdown|
| - Examples: Osimertinib, Afatinib, Dacomitinib, Sunvozertinib, Sotorasib |
+-----------------------------------------------------------------------------+
Molecular Determinants of Kinase Resistance
- Gatekeeper Mutations: Located at the entrance to the deep hydrophobic back pocket (e.g., EGFR T790M, ALK L1196M, BCR-ABL1 T315I). Bulky residue substitutions introduce steric clash that blocks first- and second-generation TKI binding without impairing physiological ATP affinity.
- Solvent-Front Mutations: Located at the solvent-exposed margin of the ATP pocket (e.g., ALK G1202R, ROS1 G2032R, NTRK1 G595R). Positively charged or bulky residues sterically displace larger flexible inhibitors while preserving kinase activity.
- Covalent Residue Mutations: Tertiary mutations at the nucleophilic cysteine residue (e.g., EGFR C797S, BTK C481S) prevent covalent bond formation, rendering irreversible covalent inhibitors ineffective.
- Off-Target Bypass Tracks: Amplification or activation of parallel signaling cascades (e.g., MET amplification, HER2 amplification, KRAS mutations, or phenotypic transformation into Small Cell Lung Cancer [SCLC]).
2. EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Epidermal Growth Factor Receptor (EGFR) activating mutations occur in approximately 15% of Western and 40–50% of Asian patients with non-squamous NSCLC. The two classical "sensitizing" mutations—Exon 19 in-frame deletions (del19) (45–50%) and Exon 21 L858R point mutations (40–45%)—confer constitutive kinase activation and marked sensitivity to EGFR TKIs.
+-----------------------------------------------------------------------------+
| EGFR TKI GENERATIONAL PROGRESSION |
| |
| 1ST GENERATION: Erlotinib, Gefitinib |
| - Reversible ATP-competitive binding; high wild-type (WT) EGFR inhibition |
| - Resistance: ~50-60% acquire EGFR T790M gatekeeper mutation within 10-14m|
| - Limited blood-brain barrier (BBB) penetration (~1-3% CSF-to-plasma ratio)|
| | |
| v |
| 2ND GENERATION: Afatinib, Dacomitinib |
| - Irreversible Pan-HER covalent inhibitors (EGFR/HER1, HER2, HER4) |
| - Improved PFS over 1st-gen, BUT potent WT-EGFR inhibition causes severe |
| Grade 3 diarrhea (15-20%) and rash; fails to fully overcome T790M in vivo|
| | |
| v |
| 3RD GENERATION: Osimertinib (FLAURA & ADAURA Standard of Care) |
| - Irreversible covalent binding to Cys797 residue |
| - Mutant-selective: High potency for Ex19del, L858R, AND T790M; spares WT |
| - Marked BBB penetration; superior CNS response and intracranial PFS |
| - Primary Resistance: Tertiary EGFR C797S mutation, MET/HER2 amplification|
+-----------------------------------------------------------------------------+
Landmark Clinical Trials in EGFR-Mutated NSCLC
- FLAURA Trial (First-Line Advanced NSCLC): Double-blind Phase 3 trial comparing osimertinib (80 mg once daily) versus standard 1st-generation TKIs (erlotinib 150 mg or gefitinib 250 mg) in treatment-naive EGFR-mutated advanced NSCLC. Osimertinib demonstrated statistically significant improvements in median progression-free survival (PFS: 18.9 vs. 10.2 months; HR 0.46, p < 0.001) and overall survival (OS: 38.6 vs. 31.8 months; HR 0.80, p = 0.046), alongside substantially lower rates of Grade >=3 adverse events and superior CNS control.
- ADAURA Trial (Adjuvant Early-Stage NSCLC): Phase 3 trial evaluating adjuvant osimertinib (80 mg daily for up to 3 years) versus placebo in resected Stage IB–IIIA EGFR-mutated NSCLC following complete surgical resection and optional adjuvant chemotherapy. Osimertinib achieved a dramatic reduction in disease recurrence or death (5-year OS: 88% vs. 78%; HR 0.49, p < 0.001).
- MARIPOSA Trial: Evaluated the combination of the bispecific EGFR-MET antibody amivantamab plus the 3rd-generation TKI lazertinib versus osimertinib monotherapy in frontline EGFR-mutated advanced NSCLC, showing prolonged median PFS (23.7 vs. 16.6 months; HR 0.70) at the expense of higher venous thromboembolism and dermatologic toxicities.
Master EGFR TKI Pharmacotherapy & Comparative Matrix
| Agent | Gen | Standard Dosing & Administration | Food Effect & Bioavailability | Acid-Suppression Interaction | Key Toxicities & Monitoring Parameters |
|---|---|---|---|---|---|
| Erlotinib | 1st | 150 mg PO daily (50 mg daily for pancreatic) | Take on an empty stomach (1 hr before or 2 hr after food). Food increases bioavailability to ~100%. | Severe interaction: Solubility decreases dramatically at pH > 5. Avoid PPIs. Space H2RAs (give erlotinib 10h after or 2h before H2RA) or antacids by 2 hours. | Acneiform papulopustular rash (75–85%), diarrhea, paronychia, elevated AST/ALT, rare interstitial lung disease (ILD/pneumonitis). |
| Gefitinib | 1st | 250 mg PO daily | With or without food. Food has no clinically significant effect. | Avoid PPIs. H2RAs and antacids must be staggered by at least 6–12 hours. | Diarrhea, rash, dry skin, elevated transaminases, corneal erosion. |
| Afatinib | 2nd | 40 mg PO daily | Take on an empty stomach (1 hr before or 2 hr after meals). Food reduces AUC by 39–50%. | No pH-dependent interaction. Can be co-administered with PPIs/H2RAs. | Severe Grade >=3 diarrhea (15–20%), stomatitis/mucositis, paronychia, skin exfoliation. P-gp substrate (dose adjust with strong P-gp inhibitors). |
| Dacomitinib | 2nd | 45 mg PO daily | With or without food. | Avoid PPIs. Local antacids or H2RAs separated by 6 hours. | High incidence of severe diarrhea, dermatitis acneiform, paronychia, alopecia. |
| Osimertinib | 3rd | 80 mg PO daily | With or without food. Minimal food effect. | No pH-dependent interaction. Can be safely co-administered with PPIs, H2RAs, and antacids. | QTc interval prolongation (monitor baseline and periodic ECG/electrolytes), cardiomyopathy (decreased LVEF in 3–5%), ILD/pneumonitis (2–4%, hold immediately if suspected), cytopenias, stomatitis. Minimal wild-type skin toxicity. |
[!IMPORTANT] EGFR Exon 20 Insertion Mutations: Classical 1st-, 2nd-, and standard 3rd-generation EGFR TKIs are inactive against EGFR exon 20 insertion mutations due to steric hindrance in the drug-binding cleft. Treatment requires specialized agents: amivantamab (an intravenous bispecific EGFR-MET antibody, preferred frontline with platinum chemotherapy per PAPILLON trial) or targeted oral exon 20 inhibitors (sunvozertinib, investigational/approved in select jurisdictions). Candidates must recognize that standard osimertinib monotherapy is not the guideline-preferred approach for exon 20 insertions.
3. ALK and ROS1 Tyrosine Kinase Inhibitors
Anaplastic Lymphoma Kinase (ALK) gene rearrangements (predominantly EML4-ALK inversions on chromosome 2p) occur in 3–5% of NSCLC, commonly in younger non-smokers. ROS Proto-Oncogene 1 (ROS1) fusions occur in 1–2% of NSCLC. Both driver oncogenes drive potent constitutive tyrosine kinase activation with high propensity for central nervous system (CNS) brain metastases (>30% at diagnosis, >60% over disease course).
+-----------------------------------------------------------------------------+
| ALK INHIBITOR GENERATIONAL SHIFT |
| |
| 1ST GENERATION: Crizotinib (PROFILE 1014) |
| - Targets: ALK, ROS1, MET |
| - P-glycoprotein substrate -> Poor BBB penetration (PFS ~10.9 months) |
| - High rate of CNS relapse as first site of progression |
| | |
| v |
| 2ND GENERATION: Alectinib, Brigatinib, Ceritinib |
| - Alectinib (ALEX Trial Standard of Care): mPFS 34.8 vs 10.9 mo; |
| CNS ORR 81%; well tolerated (myalgia, CPK, bradycardia, bilirubin) |
| - Brigatinib (ALTA-1L): mPFS 24.0 mo; unique Early-Onset Pulmonary Events |
| (EOPE) in first 7 days -> requires 90 mg to 180 mg lead-in titration |
| | |
| v |
| 3RD GENERATION: Lorlatinib (CROWN Trial) |
| - Macrocyclic compact structure; penetrates intact BBB |
| - Active against all single ALK resistance mutations including G1202R |
| - CROWN Trial: 5-year PFS >60%; HR 0.19 for CNS progression |
| - Unique Toxicities: Hypercholesterolemia (80%), hypertriglyceridemia |
| (60%), cognitive/neuropsychiatric effects (mood, speech, hallucinations)|
+-----------------------------------------------------------------------------+
Master ALK & ROS1 Inhibitor Comparison
| Kinase Inhibitor | Primary Targets | Standard Dosing & Schedule | Critical Clinical Pearls & Specific Toxicities |
|---|---|---|---|
| Crizotinib | ALK, ROS1, MET | 250 mg PO BID | Visual disturbances (photopsia/trails of light in 60%), sinus bradycardia, peripheral edema, QTc prolongation, elevated transaminases, testosterone suppression. |
| Alectinib | ALK, RET | 600 mg PO BID (take with food) | Frontline gold standard. Food increases AUC by ~3-fold. Key toxicities: Myalgia / elevated CPK (monitor CPK Q2W for first month), bradycardia, photosensitivity, elevated bilirubin (unconjugated), low incidence of rash/GI toxicity. |
| Brigatinib | ALK, ROS1, EGFR | 90 mg PO daily for 7 days, then escalate to 180 mg PO daily | Mandatory 7-day dose escalation. Early-Onset Pulmonary Events (EOPE: dyspnea, hypoxia, cough) occur within the first 3–7 days in 3–6% of patients; hold if EOPE occurs. Also causes hypertension, elevated amylase/lipase, and CPK elevation. |
| Lorlatinib | ALK, ROS1 | 100 mg PO daily | Overcomes G1202R solvent-front mutation. Causes severe lipid derangements (hypercholesterolemia in 80%, hypertriglyceridemia in 60%; initiate statin therapy [e.g., rosuvastatin or atorvastatin] promptly). Central CNS neurocognitive toxicities (mood changes, memory deficits, speech slowing, hallucinations in 20–30%; managed via dose interruption and reduction). Combined CYP3A4 substrate and moderate-to-strong inducer. |
| Entrectinib | ROS1, TRK A/B/C | 600 mg PO daily | Preferred for ROS1 fusions with CNS metastases and NTRK fusions. Toxicities: Weight gain, dizziness/ataxia, paresthesias, cognitive changes, hyperuricemia, QTc prolongation, bone fractures. |
| Repotrectinib | ROS1, TRK A/B/C | 160 mg PO daily for 14 days, then 160 mg PO BID | Next-generation macrocyclic ROS1/TRK TKI. Specifically designed to overcome ROS1 G2032R solvent-front resistance. Dizziness (70%), dysgeusia, paresthesias, ataxia, peripheral neuropathy. |
4. The MAPK Cascade: BRAF and MEK Inhibitor Combinations
Activating point mutations in the BRAF oncogene (predominantly BRAF V600E [~90%] and BRAF V600K [~10%]) result in constitutive kinase activation of the MAPK (RAS-RAF-MEK-ERK) pathway. BRAF mutations drive ~50% of cutaneous melanomas, 2–4% of NSCLC, 10% of colorectal cancers (CRC), and 40–50% of papillary/anaplastic thyroid carcinomas.
+-----------------------------------------------------------------------------+
| THE PARADOXICAL MAPK ACTIVATION PHENOMENON & MEK RESCUE |
| |
| [BRAF INHIBITOR MONOTHERAPY IN BRAF WT CELLS / RAS-PRIMED CELLS] |
| - BRAF inhibitor binds one monomer of a BRAF-CRAF wild-type heterodimer |
| - Induces transactivation and hyperphosphorylation of the adjacent CRAF |
| - Paradoxical surge in downstream MEK -> ERK signaling! |
| - Clinical Consequence: Secondary Cutaneous Squamous Cell Carcinomas |
| (cuSCC) and keratoacanthomas in 15-25% of monotherapy patients. |
| | |
| v |
| [DUAL COMBINATION: BRAF INHIBITOR + MEK INHIBITOR] |
| - MEK inhibitor blocks downstream kinase reactivation regardless of CRAF |
| - Synergistic antitumor efficacy and marked delay in disease resistance |
| - Dramatically reduces secondary skin malignancies (cuSCC < 2%) |
| - Trade-off: Introduces MEK-specific toxicities (pyrexia, LVEF decline, |
| serous retinopathy / RPED, rash, CPK elevation). |
+-----------------------------------------------------------------------------+
Dual BRAF + MEK Combinations in Oncology Practice
+-----------------------------------------------------------------------------+
| FDA-APPROVED BRAF + MEK REGIMENS IN SOLID TUMORS |
| |
| 1. DABRAFENIB + TRAMETINIB |
| - Dabrafenib: 150 mg PO BID (Empty stomach) |
| - Trametinib: 2 mg PO Daily (Empty stomach; REFRIGERATE CAPSULES) |
| - Indications: BRAF V600E Melanoma, NSCLC, Thyroid, Tumor-Agnostic |
| - Signature Toxicity: Pyrexia Syndrome (50-60%), Chills, Hypotension |
| |
| 2. ENCORAFENIB + BINIMETINIB |
| - Encorafenib: 450 mg PO Daily (Melanoma) or 300 mg Daily (CRC) |
| - Binimetinib: 45 mg PO BID |
| - Indications: BRAF V600E/K Melanoma; Encorafenib + Cetuximab in mCRC |
| - Signature Toxicity: Lower pyrexia rate, Serous retinopathy, LVEF drop|
| |
| 3. VEMURAFENIB + COBIMETINIB |
| - Vemurafenib: 960 mg PO BID |
| - Cobimetinib: 60 mg PO Daily (Days 1-21 of 28-day cycle) |
| - Indications: BRAF V600E/K Melanoma |
| - Signature Toxicity: Severe photosensitivity, QTc prolongation, CPK |
+-----------------------------------------------------------------------------+
Clinical Management Protocols for BRAF/MEK Toxicities
- Dabrafenib-Induced Pyrexia Syndrome:
- Incidence: 50–60% of patients experience fever >=38.5 deg C, often accompanied by severe rigors, diaphoresis, dehydration, and hypotension.
- Management Algorithm: At first onset of fever (>=38.5 deg C), promptly interrupt dabrafenib (and trametinib). Rule out infectious etiologies. Administer antipyretics (acetaminophen, NSAIDs). Once afebrile for >=24 hours, resume dabrafenib at the same or reduced dose. For severe, recurrent, or refractory pyrexia, initiate low-dose oral corticosteroids (prednisone 10 mg daily for 5–7 days).
- MEK Inhibitor Ocular Toxicities:
- Retinal Pigment Epithelial Detachment (RPED) / Serous Retinopathy: Fluid accumulation under the sensory retina causing blurred vision, visual field defects, or central scotomas. Usually self-limiting; hold MEK inhibitor until resolution.
- Retinal Vein Occlusion (RVO): Medical emergency causing sudden, painless unilateral vision loss. RVO mandates permanent discontinuation of MEK inhibitors.
- Cardiovascular Surveillance: Baseline and periodic echocardiograms every 2–3 months to assess Left Ventricular Ejection Fraction (LVEF); hold MEK inhibitor for absolute LVEF decline >=10% below baseline or below institutional lower limit of normal.
- Storage Requirements: Trametinib capsules must be stored refrigerated at 2 deg C to 8 deg C (36 deg F to 46 deg F) in their original bottle with desiccant to protect against moisture-induced degradation.
5. Multi-Targeted VEGFR, RET, MET, NTRK & KRAS G12C Inhibitors
Multikinase Anti-Angiogenic (VEGFR) Inhibitors
Receptor tyrosine kinases governing angiogenesis include VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha/beta, KIT, RET, and FGFR. Small-molecule VEGFR TKIs disrupt endothelial cell proliferation, survival, and vascular permeability.
+-----------------------------------------------------------------------------+
| VEGFR TKI CLASS TOXICITIES & MECHANISMS |
| |
| [ENDOTHELIAL NITRIC OXIDE SUPPRESSION & MICROVASCULAR RAREFACTION] |
| ---> Secondary Systemic Hypertension (30-60%) & Hypertensive Urgencies |
| ---> Glomerular Podocyte Disruption -> Proteinuria & Nephrotic Syndrome |
| |
| [CAPILLARY SHEAR STRESS AT PRESSURE POINTS] |
| ---> Hand-Foot Skin Reaction (HFSR / Palmar-Plantar Erythrodysesthesia) |
| |
| [PLATELET & THROMBOCYTIC DYSFUNCTION] |
| ---> Arterial Thromboembolism (MI, CVA), Bleeding, GI Perforations/Fistula|
| |
| [THYROID FOLLICULAR CAPILLARY REGRESSION] |
| ---> Destructive Thyroiditis followed by Permanent Hypothyroidism (40-70%)|
| |
| [PERIPHERAL FIBROBLAST VEGF BLOCKADE] |
| ---> Impaired Wound Healing -> Hold 1-2 weeks before/after major surgeries|
+-----------------------------------------------------------------------------+
Solid Tumor Targeted Kinase Inhibitor Master Matrix
| Kinase Class | Drug Name | Primary Target Profile | Key Indications | Signature Toxicities & BCOP Management Pearls |
|---|---|---|---|---|
| Multikinase / VEGFR | Sunitinib | VEGFR1-3, KIT, PDGFR, FLT3, RET | RCC, GIST, pNET | 4 weeks on / 2 weeks off (or continuous 37.5 mg daily). HFSR, yellow skin/hair depigmentation, hypertension, severe fatigue, cardiotoxicity, stomatitis. |
| Multikinase / VEGFR | Cabozantinib | VEGFR2, MET, AXL, RET, KIT | RCC, HCC, Medullary Thyroid | Exceedingly potent MET/AXL/VEGFR TKI. Severe diarrhea, high rate of HFSR (palmar-plantar hyperkeratosis), GI perforation/fistulae, hypertension. Take on strict empty stomach. |
| Multikinase / VEGFR | Lenvatinib | VEGFR1-3, FGFR1-4, PDGFR, RET, KIT | Differentiated Thyroid, RCC (+ Pembrolizumab), HCC, Endometrial (+ Pembrolizumab) | Rapid, severe hypertension (initiate antihypertensives proactively), proteinuria, weight loss/anorexia, QT prolongation, dysphonia. |
| Multikinase / VEGFR | Axitinib | Selective VEGFR1, 2, 3 | Advanced RCC (+ Pembrolizumab or Nivolumab) | Dose titration protocol: Start 5 mg BID, titrate up to 7 mg then 10 mg BID if BP <=150/90 without antihypertensives. Short half-life (~3–6 hours). |
| Multikinase / VEGFR | Pazopanib | VEGFR1-3, PDGFR, KIT | RCC, Soft Tissue Sarcoma | Black Box Warning for Severe Hepatotoxicity (ALT >8x ULN in 10-15%; monitor LFTs Q2W for first 9 weeks). Hair depigmentation, QTc prolongation. Take on empty stomach. |
| RET Inhibitors | Selpercatinib<br>Pralsetinib | Selective RET kinase | RET fusion NSCLC & thyroid; RET-mutated Medullary Thyroid | Highly selective over VEGFR. Toxicities: Dry mouth, hypertension, transaminitis, QTc prolongation (selpercatinib), pneumonitis and cytopenias (pralsetinib). |
| MET Exon 14 | Capmatinib<br>Tepotinib | Selective MET kinase | NSCLC with MET exon 14 skipping mutations | Peripheral edema (50–60%, manage with elevation/compression; loop diuretics ineffective), asymptomatic serum creatinine elevation via tubular transporter inhibition, ILD. |
| NTRK Inhibitors | Larotrectinib<br>Entrectinib | TRK A, TRK B, TRK C | Tumor-agnostic NTRK gene fusions | Remarkable response rates (>75%). Neurocognitive toxicities (dizziness, ataxia, memory changes), rapid weight gain/hyperphagia, paresthesias, rebound withdrawal pain upon sudden TKI cessation. |
| KRAS G12C | Sotorasib<br>Adagrasib | Mutant KRAS(G12C) GDP-bound state | KRAS G12C-mutated NSCLC & Colorectal Cancer | Sotorasib: Hepatotoxicity, diarrhea. Adagrasib: QTc prolongation, nausea/vomiting, transaminitis. Adagrasib is a strong CYP3A4 inhibitor and substrate. |
6. Pharmacist-Led Toxicity Interception & Practice Standards
+-----------------------------------------------------------------------------+
| PHARMACIST-LED MANAGEMENT OF TKI DERMATOLOGIC TOXICITIES |
| |
| [EGFR ACNEIFORM RASH] [VEGFR HAND-FOOT SKIN REACTION] |
| - Pathophysiology: Follicular - Pathophysiology: Subcorneal |
| inflammation, NO comedones! intraepidermal blister / hyper- |
| - Prophylaxis (STEPP Protocol): keratosis at friction points. |
| * Oral Doxycycline or Minocycline - Prophylaxis & Management: |
| 100 mg PO BID x 6-8 weeks * Pre-treatment podiatry/debulk |
| * Topical Hydrocortisone 1% cream * Prophylactic Urea 10-20% cream|
| * Broad-spectrum SPF 30+ sunscreen * Soft shoe insoles / no friction|
| * Alcohol-free emollients/moisturizer * Clobetasol 0.05% for Grade 2/3|
+-----------------------------------------------------------------------------+
Critical Pharmacokinetic Drug Interaction Rules
- Gastric pH-Dependent Bioavailability: Erlotinib, gefitinib, and dasatinib require an acidic gastric microenvironment for tablet dissolution. Concomitant Proton Pump Inhibitors (PPIs: omeprazole, pantoprazole) chronically elevate gastric pH >5, reducing TKI systemic AUC by 50–70% and leading to disease progression. In contrast, 3rd-generation osimertinib and 2nd-generation afatinib are pH-independent and can be co-prescribed with PPIs without loss of exposure.
- Cytochrome P450 3A4 (CYP3A4) Management: The vast majority of oral TKIs undergo primary hepatic clearance via CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, posaconazole, clarithromycin) requires a 50% dose reduction for most TKIs. Co-administration with strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) should be avoided as it dramatically accelerates drug clearance, rendering therapy subtherapeutic.
A 64-year-old patient with metastatic non-small cell lung cancer harboring an EGFR exon 19 deletion has been receiving first-line erlotinib 150 mg orally daily for 6 months with stable disease. Two months ago, the patient was prescribed omeprazole 40 mg daily by their primary care physician for severe gastroesophageal reflux disease. Today, restaging CT scans demonstrate progressive primary lung nodules and new pleural metastases. Plasma therapeutic drug monitoring reveals an erlotinib serum concentration 65% below the expected steady-state minimum. What pharmacokinetic mechanism explains this therapeutic failure?
A 56-year-old male with BRAF V600E-mutated metastatic melanoma is initiated on combination targeted therapy with dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily. On Day 18 of therapy, he presents to the oncology clinic with a temperature of 39.4°C (103.0°F), severe rigors, diaphoresis, and mild lightheadedness (blood pressure 96/60 mmHg). Infectious workup, including blood cultures, urinalysis, and chest radiography, reveals no bacterial or viral source. Which of the following represents the most appropriate evidence-based clinical pharmacist intervention for managing this adverse event?
A 61-year-old woman with advanced EGFR L858R-mutated NSCLC experienced disease progression after 14 months of frontline gefitinib therapy. A liquid biopsy at progression revealed the emergence of the EGFR T790M gatekeeper mutation, and she was successfully transitioned to second-line osimertinib 80 mg daily. After 18 months of durable response on osimertinib, repeat NGS sequencing from a progressing liver metastasis identifies the original L858R mutation, the T790M mutation, and a new EGFR C797S point mutation occurring on the same DNA allele (in cis). Why does the emergence of this tertiary C797S mutation confer complete resistance to osimertinib?
A 58-year-old patient with metastatic clear cell renal cell carcinoma (ccRCC) begins treatment with the multi-targeted tyrosine kinase inhibitor cabozantinib 60 mg orally daily. Three weeks after starting therapy, the patient presents with severe erythema, localized hyperkeratosis, painful blistering, and intense burning on the heel and metatarsal heads of both feet, making ambulation extremely painful (Grade 3 toxicity). What is the underlying pathophysiology of this adverse effect, and what is the optimal clinical management strategy?